Benitec Biopharma
BNTC
18 hedge funds and large institutions have $5.43M invested in Benitec Biopharma in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
21% more capital invested
Capital invested by funds: $4.47M → $5.43M (+$953K)
13% more funds holding
Funds holding: 16 → 18 (+2)
0.04% less ownership
Funds ownership: 1.14% → 1.1% (-0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$119K |
| 2 |
VF
Virtu Financial
New York
|
+$88.5K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$74.1K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.9K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$7.75K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$181K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$87K |
| 3 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$46K |
| 4 |
BlackRock
New York
|
-$15.2K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$66 |
BNTC Hedge Fund Activity: Q3 2021 in Review
18 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q3 2021, worth a combined $5.43M — up 21% from $4.47M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BNTC positions and 3 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Silverarc Capital Management, adding an estimated $119K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $181K sold.
- 18 institutional investors held Benitec Biopharma (BNTC) as of Q3 2021, up from 16 in Q2 2021.
- Funds reported $5.43M of Benitec Biopharma stock for Q3 2021, up 21% quarter-over-quarter.
- 5 funds opened new Benitec Biopharma positions in Q3 2021 and 3 closed out, a net change of +2 holders.
- The largest Benitec Biopharma buyer in Q3 2021 was Silverarc Capital Management, an estimated $119K added.
- The largest Benitec Biopharma seller in Q3 2021 was Renaissance Technologies, an estimated $181K sold.
Based on aggregated 13F filings for Q3 2021.